^
Association details:
| Biomarker: | BRAF fusion |
|---|---|
| Cancer: | Glioma |
| Drug: | ulixertinib (BVD-523) (ERK2 inhibitor, ERK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J).
Published date:
05/26/2022
Excerpt:
The pediatric RP2D of ulixertinib was established as 260 mg/m2/dose PO BID....Three patients with CNS tumors achieved stable disease > 6 months (HGG with BRAF fusion, 15 cycles; glioneuronal tumor with BRAF V600E, 9 cycles; low-grade glioma with BRAF fusion, 7 cycles)…. Clinical benefit of prolonged disease control was observed in 3 patients with BRAF-altered gliomas and glioneuronal tumors.
DOI:
10.1200/JCO.2022.40.16_suppl.3009
